Nomic Publishes Foundational Protein Quantification Technology in Nature Methods
Nomic Bio (“Nomic”) today announced publication of its core nELISA® technology in Nature Methods, detailing a high‑throughput, high‑plex immunoassay platform that side-steps reagent‑driven cross‑reactivity to maintain exquisite specificity at scale. Coinciding with the publication, Nomic unveiled a 1.4 million-data-point PBMC cytokine perturbation dataset in the Nomic Portal, an intuitive platform for exploring and analyzing proteomic data.
Nomic Bio Awards Omni 1000 Proteomics Grants to Seven Institutions, Enabling 5 Million Data Points Across 5,000 Samples
Nomic Bio (“Nomic”), the Protein Profiling Company, today announced the recipients of its Omni 1000 High-Plex Proteomics Grant, a program designed to expand access to proteomics with the company’s Omni 1000 solution and Nomic platform. The grant will support seven research groups profiling more than 5,000 samples and generating over 5 million datapoints, advancing Nomic’s mission to make proteomics accessible at scale.
Nomic Bio Debuts $50 Proteome with Absolute Quantification Through Launch of Omni 1000
Nomic Bio ("Nomic"), the Protein Profiling Company, today announced the launch of Omni 1000—a transformative high-plex solution now available through Nomic’s end-to-end service platform.
Nomic® Secures $42M in Oversubscribed Series B to Expand Access to Protein Profiling
Nomic Bio ("Nomic"), the Protein Profiling company, today announces the completion of an oversubscribed $42 million Series B funding round. The fresh capital will enable Nomic to accelerate the expansion of its commercial operations, further invest in advancing its state-of-the-art protein profiling platform, and broaden its transformative offerings to meet growing demand.
Nomic Bio Appoints Byron Hewett to its Board of Directors
Nomic Bio, a pioneering protein profiling company, today announced the appointment of Byron Hewett to its board of directors. Hewett brings invaluable operational and strategic expertise to guide Nomic Bio through its crucial years of growth.
Nomic to Provide nELISA to JUMP Cell Painting Consortium to Measure Protein Secretome for Phenotypic Drug Discovery
Nomic Bio ("Nomic"), the protein profiling company, announced today that it is providing access to the company’s nELISATM platform to the Joint Undertaking in Morphological Profiling-Cell Painting (JUMP-CP) consortium. The JUMP-CP consortium is coordinated by the Imaging Platform at the Broad Institute of MIT and Harvard and brings together pharma and biotech companies and non-profit partners to create the world’s largest public cell-imaging database to accelerate phenotypic drug discovery. The database, which is scheduled to be publicly available in November 2022, will display the phenotypes of more than one billion cells responding to over 140,000 small molecules and genetic perturbations to enable a systematic mapping of the activity and toxicity of compounds, as well as their associations to relevant disease states. As part of the collaboration, Nomic will provide JUMP-CP scientists and partners the ability to measure 200 secreted proteins in 10,000 samples, which will generate two million protein data points.
Nomic Closes $17 Million Series A to Develop and Commercialize the World’s Highest Throughput Proteomic Platform
Nomic Bio ("Nomic"), the protein profiling company, today announced the closing of an oversubscribed US$17 million Series A funding round, bringing the company's total funding to date to over US$21 million. The round was led by Lux Capital and joined by SR One and Casdin Capital, with participation from prior institutional investors.
